MediaMedic

EBMT 2025 | GVHD Prophylaxis in Haploidentical HSCT for R/R AML: Insights from Dr. Giorgia Battipaglia

By Mourabit Halima 2025.04.12

At EBMT 2025, Dr. Giorgia Battipaglia shared important findings from a multicenter study comparing post-transplant cyclophosphamide (PTCy) versus antithymocyte globulin (ATG) as GVHD prophylaxis in patients with relapsed/refractory AML undergoing…

GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial

By Mourabit Halima 2025.04.12

At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in…

ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC

By Yin, Jiale 2025.04.12

At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.

ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital

By Mourabit Halima 2025.04.11

At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.

Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL

By Mourabit Halima 2025.04.11

At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival…

EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes

By Peter W. PENG 2025.04.11

At this year’s EBMT Annual Meeting, Dr. María-Victoria Mateos (Salamanca, Spain) delivered an impactful presentation titled “MRD in Myeloma as Surrogate Marker for Outcomes.”

Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape

By Mourabit Halima 2025.04.11

At EBMT 2025, Yasmina Serroukh from Erasmus MC presented a benchmark study evaluating the role of allogeneic stem cell transplantation (allo-SCT) in follicular lymphoma (FL). The analysis, drawn from a…

Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination

By Peng Longmei 2025.04.11

In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…

Can we truly personalize leukemia-free survival prediction after allo-HCT?

By Mourabit Halima 2025.04.11

At EBMT 2025, Professor Alexandros Spyridonidis delivered a compelling presentation addressing one of the most pressing challenges in hematopoietic stem cell transplantation: how to provide patients with accurate, individualized prognostic information.

Evaluating FMT in Hepatic Encephalopathy: Insights from the THEMATIC Trial

By Mourabit Halima 2025.04.11

In a recent editorial published in the Journal of Hepatology (March 24, 2025), Professors Debbie Shawcross and Vishal C. Patel spotlight the THEMATIC trial—a phase II RCT investigating the safety…

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance

Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

EBMT 2025 | GVHD Prophylaxis in Haploidentical HSCT for R/R AML: Insights from Dr. Giorgia Battipaglia

GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial

ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC

ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital

Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL

EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes

Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape

Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination

Can we truly personalize leukemia-free survival prediction after allo-HCT?

Evaluating FMT in Hepatic Encephalopathy: Insights from the THEMATIC Trial

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.